Most Read Articles
Roshini Claire Anthony, 20 Oct 2020

The increased risk of mortality among patients with cancer diagnosed with COVID-19 may be due to their older age and presence of comorbidities, according to a study presented at ECCVID 2020.

Pank Jit Sin, 02 Nov 2020
Application for Sputnik V, the tradename of the world’s first registered COVID-19 vaccine, has been submitted to the WHO for accelerated registration via the Emergency Use Listing (EUL) and prequalification. 

Poor BP control worsens COVID-19 in hypertensive patients

6 days ago

Hypertensive patients with the novel coronavirus disease (COVID-19) who have poor blood pressure (BP) control are at greater risk of worse outcomes, a recent China study has found. In contrast, the use of angiotensin II receptor blockers (ARB) does not seem to worsen disease outcomes.

The researchers retrospectively assessed the anonymized records of 803 hypertensive COVID-19 patients. Disease outcomes included mortality, admission into the intensive care unit (ICU), and respiratory and heart failure, which were assessed with regard to BP control.

At baseline, 609 patients had available BP information. Nearly half had normal measurements, with mean systolic (SBP) and diastolic BP (DBP) values of 137.0±19.7 and 84.2±12.8 mm Hg, respectively. Overall, 82.4 percent (n=662 of 803) were deemed to have good BP control.

Cox proportional hazards analysis revealed that average SBP was a significant and independent predictor of heart failure (hazard ratio [HR] per 10 mm Hg, 1.89, 95 percent confidence interval [CI], 1.15–3.13). The same was true for pulse pressure (PP; HR per 10 mm Hg, 2.71, 95 percent CI, 1.39–5.29).

In addition, greater SBP variability emerged as a significant risk factor for both mortality (HR per 1 mm Hg, 1.23, 95 percent CI, 1.11–1.36) and ICU admission (HR per 1 mm Hg, 1.12, 95 percent CI, 1.05–1.20). DBP variability had the same effect (mortality: HR per 1 mm Hg, 1.33, 95 percent CI, 1.12–1.75; ICU admission: HR per 1 mm Hg, 1.20, 95 percent CI, 1.08–1.33). There were no BP factors associated with respiratory failure.

In terms of medication, patients on ARB saw a significantly lower risk of ICU admission (HR, 0.21, 95 percent CI, 0.06–0.73).

“ARB drugs did not cause higher risks of adverse outcomes in hypertensive patients, and even a benefit in regard to heart failure was observed. This supports the continuation of ARB drugs in COVID-19 patients,” the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 20 Oct 2020

The increased risk of mortality among patients with cancer diagnosed with COVID-19 may be due to their older age and presence of comorbidities, according to a study presented at ECCVID 2020.

Pank Jit Sin, 02 Nov 2020
Application for Sputnik V, the tradename of the world’s first registered COVID-19 vaccine, has been submitted to the WHO for accelerated registration via the Emergency Use Listing (EUL) and prequalification.